Anxiety Disorders and Depression Treatment Market to Reach USD 16.65 Billion by 2032, Growing at 3.53% CAGR | By S&S Insider
25 oct. 2024 09h00 HE
|
SNS Insider pvt ltd
Austin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The S&S Insider report indicates that, “The Anxiety Disorders and Depression Treatment Market was USD 12.2 billion in 2023 and is likely to reach USD...
Nexstim Receives NBS System 5 Order from European Customer
02 oct. 2024 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 2 October 2024 at 9 AM (EEST) Nexstim Receives NBS System 5 Order from European Customer Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS...
Anxiety Disorders and Depression Treatment Global Market Report 2024-2032: Sturdy Medication Pipelines to Support Development, Economic Cost of Mental Illnesses to Drive Demand
30 août 2024 04h15 HE
|
Research and Markets
Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Anxiety Disorders and Depression Treatment Global Market Report, Forecast by Product, Indication, Country and Company Analysis 2024-2032" report has...
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
01 juil. 2024 04h30 HE
|
Nexstim Oyj
Press release, Helsinki, 1 July 2024 at 11:30 AM (EEST) US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received...
Finnish Hospital Orders Nexstim NBS System 5
08 mai 2024 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 8 May 2024 at 9 AM (EEST) Finnish Hospital Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a...
Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region
13 mars 2024 14h13 HE
|
Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution...
Postpartum Depression Market & Epidemiology Research Report 2023-2032: Focus on ZULRESSO (Brexanolone), SAGE-217, and Ganaxolone
29 janv. 2024 13h01 HE
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "Postpartum Depression - Market Insights, Epidemiology, and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. ...
Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients
04 janv. 2024 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression...
TrustPoint Hospital Offers Electroconvulsive Therapy in Inpatient & Outpatient Programs
07 nov. 2023 12h11 HE
|
TrustPoint Hospital
MURFREESBORO, Tenn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- TrustPoint Hospital, a top provider of behavioral health treatment in Tennessee, offers electroconvulsive therapy (ECT) for adults who are...
Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
17 mai 2023 07h00 HE
|
Nexstim Oyj
Press release, Helsinki, 17 May 2023 at 2 PM (EEST) Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received...